You are here

  • Home
  • Archive
  • Volume 20, Issue 7
  • Is There a High-Risk Subgroup of Stage I Epithelial Ovarian Cancer that Is Most Likely to Benefit From 6 Versus 3 Cycles of Adjuvant Chemotherapy?

Article info

Article menu
Download PDFPDF
Ovarian Cancer
Is There a High-Risk Subgroup of Stage I Epithelial Ovarian Cancer that Is Most Likely to Benefit From 6 Versus 3 Cycles of Adjuvant Chemotherapy?

Authors

  1. Address correspondence and reprint requests to Jamie N. Bakkum-Gamez, MD, Division of Gynecologic Surgery, Mayo Clinic, 200 1st St SW, Rochester, MN 55905. E-mail: bakkum.jamie{at}mayo.edu.

Citation

Bakkum-Gamez JN, Richardson DL, Seamon LG, et al
Is There a High-Risk Subgroup of Stage I Epithelial Ovarian Cancer that Is Most Likely to Benefit From 6 Versus 3 Cycles of Adjuvant Chemotherapy?
International Journal of Gynecologic Cancer 2010;20:1125-1131.

Publication history

  • Received February 15, 2010
  • First published October 1, 2010.
Online issue publication 
December 03, 2018

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Copyright © 2010 by IGCS and ESGO